Reading this on a mobile device? Try our optimized mobile version here: https://r.smartbrief.com/resp/efaBCfbwnseYjzdxHQBs

January 11, 2013
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • Major pharma eyes mid-priced biotech M&A deals in 2013
    Big drugmakers with expired patents on major products will increasingly depend on mergers and acquisitions to increase sales, according to an analysis from Ernst & Young. Demand is expected to be high for biotech firms in the $5 billion to $20 billion range, particularly for "bolt-on" operations that can contribute to sales immediately. Xconomy/San Francisco (1/10) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Bigger, lengthier clinical trials could help in finding a cure for ALS
    More than 20 experimental drugs have failed in clinical trials as treatments for amyotrophic lateral sclerosis. Biogen Idec's dexpramipexole was abandoned when it failed to help patients in a phase III trial. Steve Perrin, CEO of the ALS Therapy Development Institute, says that phase II trials should involve more patients for longer periods to determine how to proceed in phase III. "All of the drugs that have failed recently in Phase III looked promising at Phase II," he said. "The lesson here is that we need to change the design in Phase II." Xconomy/Boston (1/10) LinkedInFacebookTwitterEmail this Story
  • Theravance and GSK submit COPD combo for EU review
    GlaxoSmithKline and Theravance filed an application with the European Medicines Agency seeking approval to market Anoro, their once-daily inhaler UMEC/VI, as a maintenance treatment for symptom relief in adult patients with chronic obstructive pulmonary disease. The drug is a combination of vilanterol, a long-acting beta agonist, and umeclidinium bromide, a long-acting muscarinic antagonist. PharmaTimes (U.K.) (1/10) LinkedInFacebookTwitterEmail this Story
  • Mesoblast's spinal treatment may enter late-stage trial this year
    Mesoblast plans to launch a late-stage trial this year of NeoFuse, a mesencyhmal precursor stem cell treatment for spinal fusion, after announcing promising results from a midstage study. Patients in the Phase II trial who received 25 million mesenchymal precursor cells had higher fusion rates after 12 months than those who got bone autograft. The treatment also was associated with diminished surgical blood loss, according to the study. Australian Life Scientist (1/11) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Galapagos wins $3.5M grant for antibiotics research
    A Flemish agency awarded Galapagos a grant worth about $3.5 million to discover new antibiotics. The firm will work with researchers from Ghent University and Free University Brussels in this three-year project. "With this grant, we can support the search for more novel inhibitors of the antibacterial target DNA pol III alpha to fight against these difficult-to-treat bacterial species," Galapagos Chief Scientific Officer Piet Wigerinck said. Genetic Engineering & Biotechnology News (1/10) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  Industrial & Environmental 
  • DuPont is optimistic about 2nd-generation biofuel projects
    DuPont Industrial Biosciences is working on two second-generation biofuel projects it believes it can commercialize, said Jan Koninckx, global director of biofuels. The company's corn-stover facility in Nevada, Iowa, which broke ground in November, will gather stover from up to 40 miles away, provided by about 100 farmers under contract. DuPont also has high hope for its Butamax Advanced Biofuels joint venture with BP, which will be the first such to produce isobutanol from corn using a genetically modified yeast, Koninckx said. ConsumerEnergyReport.com (1/7) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
The most valuable of all talents is that of never using two words when one will do."
--Thomas Jefferson,
3rd U.S. president


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information